AIM:To systemically evaluate the clinical efficacy and safety of treating allergic conjunctivitis with olopatadine eye drops and other therapies.

METHODS: We performed a comprehensive search for the randomized controlled trials(RCTs)about the olopatadine eye drops and other therapies vs. olopatadine eye drops monotherapy for treating allergic conjunctivitis published by April, 2016 from PubMed, EMbase, Cochrane Library, VIP Chinese periodical Database, CNKI and Wan Fang Chinese periodical Database. Studies obtained from eligible database were filtered according to the criteria, and data were retrieved from those studies for further analysis. Then we performed a Meta-analysis using RevMan 5.3 software.

RESULTS: A total of 28 RCTs were included. Among all 3568 patients involved in, 1 799 were in the treatment group, while the other 1 769 were in the control group. The results of Meta-analysis showed that the olopatadine eye drops and other therapies was superior to monotherapy for patients with allergic conjunctivitis in clinical effects \〖OR=3.54,95%CI(2.71,4.61),P<0.001\〗.

CONCLUSION: The existing evidence supports that the prognosis of the olopatadine eye drops and other therapies is better than olopatadine eye drops monotherapy for treating allergic conjunctivitis. For the quality and quantity limitations of the included studies, more well-designed and double blind RCTs are required to further prove this conclusion.